Helicobacter pylori Eradication, Acid Suppression, and Upper GI Endoscopic Management
This research community focuses on the clinical management of Helicobacter pylori infection, the treatment of acid-related gastrointestinal disorders, and the endoscopic diagnosis and intervention of upper digestive tract conditions.
The work centers on optimizing antibiotic regimens, specifically bismuth quadruple therapy and rifasutenizol-based combinations, to eradicate H. pylori while addressing rising antibiotic resistance. A significant portion of the literature evaluates the efficacy and safety of proton pump inhibitors and potassium-competitive acid blockers for managing gastroesophageal reflux disease and peptic ulcer complications. Endoscopic procedures are a major methodological focus, including peroral endoscopic myotomy for achalasia, screening for gastric cancer, and the management of dysphagia. The community also investigates the relationship between H. pylori eradication and gastric cancer prevention, alongside the role of probiotics and microbiota modulation in treatment outcomes.
The largest share of this community's output is found in barium research, accounting for 4.4% of all barium-related papers, followed by bismuth at 3.0%. Barium also contributes the highest raw paper count within this group, with 2,226 papers.
The community comprises 11,955 papers, with the most frequent venues being Gastroenterology, World Journal of Gastroenterology, and Helicobacter.
Recent work continues to refine H. pylori treatment protocols, including new consensus guidelines for screening and eradication, and the evaluation of novel drug delivery systems like nanoemulsions to improve antibiotic efficacy.